NGNikolaos A. Georgiadis

Nikolaos A. Georgiadis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikolaos A. Georgiadis has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neutrophil extracellular trap suppression in rheumatoid arthritis patients treated with biologic therapy: a prospective observational study

    by Georgios V. Papamichail, Akrivi Chrysanthopoulou, Nikolaos A. Georgiadis, Christina A. Kapsali, Vasileios G. Xydis, Athanasios Kitsakos, Alexandros A. Drosos, Paraskevi V. Voulgari

    Background: Rheumatoid arthritis (RA) is associated with increased cardiovascular risk, partly driven by chronic systemic inflammation. Neutrophil extracellular traps (NETs) have emerged as important mechanistic links between sustained immune activation and early vascular injury. Objective: To evaluate changes in NET-associated activity following initiation of biologic therapy in patients with RA and to investigate the relationship between treatment- associated changes in NETs, lipid profile, and subclinical atherosclerosis. Methods: In this prospective single-arm observational study, 36 patients with RA initiating biologic therapy were evaluated at baseline and after 6 months of treatment. Disease activity was assessed using DAS28-CRP, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). Circulating citrullinated histone H3 (CitH3) levels were measured by ELISA as a robust marker of NETs. Carotid intima-media thickness (cIMT) was assessed using high-resolution B-mode ultrasonography. Linear regression analyses were performed to investigate the relationship between NETs activity, inflammatory burden, lipid profile, and subclinical atherosclerosis, both cross-sectionally and longitudinally following biologic therapy. Results: Following initiation of biologic therapy, disease activity and inflammatory markers improved significantly. Circulating CitH3 levels decreased from a median 3.89 (0.11–32.78) to 2.56 (0.07–8.39; p -value 0.025) while cIMT decreased from a median 1 (0.7–1.6) mm to 0.75 (0.6–1.3 mm; p -value < 0.001) after 6 months of treatment. HDL cholesterol increased significantly from 56.36 ± 16.21 to 67.47 ± 17.56 mg/dL ( p < 0.001). At follow-up, CitH3 levels were independently associated with ESR (β = 0.448, p = 0.018), indicating a relationship between NETs and systemic inflammatory burden. Longitudinal analyses demonstrated that changes in HDL cholesterol were independently associated with changes in CitH3 (β = − 0.505, p = 0.003), whereas changes in DAS28, CRP, ESR, oxLDL, and cIMT were not independently associated with ΔCitH3. No significant differences in ΔCitH3 were observed between anti-TNF and non-anti-TNF therapies. Conclusions: In this prospective observational cohort, initiation of biologic therapy was associated with reduced circulating CitH3 levels, alongside improvements in disease activity, inflammatory markers, HDL cholesterol, and cIMT. The longitudinal association between increases in HDL cholesterol and reductions in CitH3 was independent of changes in disease activity and cIMT, generating a hypothesis regarding a potential immunometabolic relationship between HDL cholesterol and NET-associated activity. These findings should be considered exploratory and require confirmation in larger, controlled prospective studies. Key Points • Biologic therapy was associated with a significant reduction in circulating CitH3 levels, consistent with reduced NET-associated activity in patients with RA. • Changes in HDL cholesterol independently predict changes in NETs, suggesting a possible HDL–NETs immunometabolic axis in RA patients under biologic treatment. • Concurrent improvement in NETs and subclinical atherosclerosis supports a potential role for NETs in RA-associated cardiovascular risk. • Similar reductions in CitH3 were observed across biologic treatment classes; however, the small and unequal subgroup sizes limit the ability to draw conclusions regarding class-specific effects.

  • Subclinical atherosclerosis in patients with undifferentiated connective tissue disease: comparison with rheumatoid arthritis

    by Georgios V. Papamichail, Nikolaos A. Georgiadis, Vasileios G. Xydis, Iro Rapti, Christina A. Kapsali, Athanasios Kitsakos, Alexandros A. Drosos, Paraskevi V. Voulgari

    To investigate the lipid profile and subclinical atherosclerosis in patients with undifferentiated connective tissue disease (UCTD), in comparison with rheumatoid arthritis (RA) and healthy individuals. This cross-sectional controlled study included 30 patients with UCTD, treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), 59 patients with RA receiving csDMARDs, and 31 age- and sex-matched healthy controls. All participants had no history or presence of coronary artery disease, hypertension, diabetes mellitus, dyslipidemia, thyroid disease, smoking, and none received diuretics, cholesterol-lowering drugs, or other agents affecting the lipid profile. Fasting serum lipid parameters such as total cholesterol (TC), triglycerides (TGL), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured in all patients and controls. Subclinical atherosclerosis was assessed by measuring carotid intima-media thickness (cIMT) using ultrasonography. UCTD patients exhibited significantly lower TC and HDL-C levels compared with controls (204.4 ± 43.0 mg/dL vs 238 ± 41.4 mg/dL, p < 0.004 and 50.6 ± 9.5 mg/dL vs 61.3 ± 13.3 mg/dL, p < 0.002 respectively). They also presented with increased cIMT compared to healthy controls (0.8 [0.6-1.5] mm vs 0.6 [0.5-0.7] mm, p < 0.001). No differences were observed in TGL and LDL-C among UCTD and healthy controls. RA patients demonstrated higher cIMT (in unadjusted analyses) and HDL-C compared to UCTD patients (0.9 [0.8-1.0] mm vs 0.8 [0.6-1.5] mm, p < 0.001 and 56.8 ± 15.2 mg/dL vs 50.6 ± 9.5 mg/dL, p < 0.004 respectively). However, after multivariable linear regression analysis adjusting for age, sex, ESR, and disease duration, disease type was not independently associated with cIMT (β = 0.02, 95% CI - 0.16 to 0.19; p = 0.86). Subclinical atherosclerosis was observed in both RA and UCTD patients compared with healthy controls. Although RA patients exhibited higher cIMT values in unadjusted analyses, disease type was not independently associated with cIMT after multivariable adjustment. These findings suggest that cumulative inflammatory burden rather than diagnostic category alone may contribute to vascular alterations. Prospective longitudinal studies are required to clarify cardiovascular risk evolution in UCTD. Key Points • Patients with UCTD exhibit subclinical atherosclerosis despite conventional immunosuppressive treatment. • RA patients show a greater burden of subclinical atherosclerosis compared with UCTD patients in unadjusted analyses. • Quantitative lipid levels partly explain cardiovascular risk in inflammatory rheumatic diseases, highlighting the role of endothelial dysfunction and immune-mediated mechanisms.